Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes

Authors

Keywords

Journal

Volume 19, Issue 9, Pages 2468-2473

Publisher

Elsevier BV

Online

2009-03-15

DOI

10.1016/j.bmcl.2009.03.036

Discuss science. Find collaborators. Network.

Join a conversation

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now